Diana Rabadi Marar, MD
Internal Medicine · Council Bluffs, IANPI 1366458945
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,848 of the $25,462 with a category attached, or 85.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,299 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Amgen$2K
- Bayer$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Novo Nordisk AS$2K
- plus $13K from 54 others
Across 25 payments — averaging $175.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$3K
- Gilead$1K
What the payments were for
- Speaking & faculty fees$1,2785%
- Travel & lodging$1,3665%
- Food & beverage$21,84886%
- Education$9704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,462 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 167 | $215,616 |
| FarxigaDapagliflozin Propanediol | 197 | $183,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $127,536 |
| KerendiaFinerenone | 148 | $110,330 |
| EliquisApixaban | 88 | $70,795 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $65,230 |
| XareltoRivaroxaban | 84 | $64,666 |
| XifaxanRifaximin | 21 | $63,663 |
| TrulicityDulaglutide | 53 | $53,773 |
| MyrbetriqMirabegron | 74 | $51,414 |
| JardianceEmpagliflozin | 48 | $46,718 |
| Repatha SureclickEvolocumab | 59 | $34,975 |
| JanuviaSitagliptin Phosphate | 69 | $33,232 |
| GemtesaVibegron | 45 | $27,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $24,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,178 | $269,389220 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,955 | $212,345236 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $469 | $134,413167 claims |
| BayerKerendia | $1,987 | $110,330148 claims |
| PfizerEliquis | $970 | $70,79588 claims |
| Johnson & JohnsonXarelto | $845 | $64,66684 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $304 | $63,66321 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $1,070 | $58,08286 claims |
| MerckJanuvia, Belsomra | $601 | $51,597102 claims |
| Boehringer IngelheimJardiance | $385 | $46,71848 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $242 | $27,92245 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $412 | $22,49243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Council Bluffs
- Alan KricsfeldCouncil Bluffs$49K
- Matthew FryzekCouncil Bluffs$28K
- Isam MararCouncil Bluffs$23K
- Barry KricsfeldCouncil Bluffs$13K
- Vikrant SalariaCouncil Bluffs$7K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Aziz HammoudIowa City$29K
- Ali SaeedCedar Rapids$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.